Clinical trial NCT01478269: Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen
Official title: Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen (ProDLBCL)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: B-Cell Lymphomas
Keywords: Aggressive B-cell lymphoma
R-CHOP
Lead sponsor: Fondazione Italiana Linfomi - ETS
Sponsor class: OTHER
First posted: 2011-11-23
Enrollment: 1927
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Cases of aggressive B-cell lymphoma diagnosed between 2001 to 2007 in Italy

Brief summary: This study is a retrospective analysis of an homogeneous population of patients with aggressive B-cell lymphoma and treated upfront with R-CHOP or R-CHOP like regimens to reassess the prognostic factors and hopefully to identify more accurate prognostic subgroups with a clinical and therapeutical relevance.


Eligibility criteria: Inclusion Criteria:

1. Histologically confirmed newly diagnosed aggressive B-cell lymphoma according to the current World Health Organisation Classification, from 2001 to 2007.
2. Any stage of disease.
3. Treatment with R-CHOP or R-CHOP like regimens (+/- transplant).
4. Age at least 18 years.
5. Availability of tissue biopsy at diagnosis for a possible centralized revision.
6. Availability of data on clinical involvement, laboratory, treatment and follow up.

Exclusion Criteria:

* None

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Campinas
country: Brazil
facility: Hemocentro-Unicamp
city: Santa Isabel
country: Brazil
facility: Centro Medico
city: Sao Paolo
country: Brazil
facility: Centro Paulista de Oncologia
city: Sao Paolo
country: Brazil
facility: Santa Casa Medical School
city: Alessandria
country: Italy
facility: A.O.SS. Biagio, Antonio e Cesare Arrigo
city: Aviano (Pordenone)
country: Italy
facility: Centro di riferimento Oncologico Oncologia Medica A
city: Bergamo
country: Italy
facility: USC Ematologia e Trapianto di Midollo Osseo Ospedali Riuniti di Bergamo
city: Brindisi
country: Italy
facility: Presidio Ospedaliero A.Perrino - Divisione di Ematologia
city: Busto Arsizio
country: Italy
facility: U.O. di Oncologia Ospedale di Circolo di Busto Arsizio
city: Camposanpiero (PD)
country: Italy
facility: Ospedale Civile
city: Catanzaro
country: Italy
facility: A.O.Pugliese Ciaccio Diviisone di Ematologia
city: Cosenza
country: Italy
facility: Presidio Ospedaliero Annunziata U.O.C. di Ematologia
city: Firenze
country: Italy
facility: Clinica Ematologica Policlinico Carreggi
city: Genova
country: Italy
facility: Ematologia 1 Ospedale S. Martino
city: Genova
country: Italy
facility: Oncologia Medica B e C IST Genova
city: La Spezia
country: Italy
facility: Ospedale Felettino
city: Matera
country: Italy
facility: Ospedale Madonna delle grazie U.O. Ematologia
city: Messina
country: Italy
facility: A O Papardo
city: Messina
country: Italy
facility: Azienda Ospedaliero Universitaria Policlinico Gaetano Martino
city: Milano
country: Italy
facility: Ematologia e Trapianto IRCCS, Istituto Nazionale dei Tumori
city: Milano
country: Italy
facility: Oncologia Medica 3 Istituto Nazionale dei Tumori di Milano
city: Milano
country: Italy
facility: Osp. San Carlo Borromeo Divisione di Oncologia Medica
city: Milano
country: Italy
facility: Ospedale Maggiore IRCCS-Dipartimento di Ematologia
city: Modena
country: Italy
facility: Centro Oncologico Modenese
city: Novara
country: Italy
facility: A.O. Maggiore della Carità S.C.D.U. Ematologia
city: Padova
country: Italy
facility: A.O. di Padova Divisione di Oncologia Medica
city: Palermo
country: Italy
facility: Casa di cura La Maddalena Unita' di Ematologia
city: Palermo
country: Italy
facility: Div. di Ematologia e TMO AOU Policlinico Giaccone di Palermo
city: Parma
country: Italy
facility: A O Universitaria di Parma
city: Piacenza
country: Italy
facility: Ospedale Civile G.da Saliceto - UOA Ematologia
city: Pisa
country: Italy
facility: Azienda Ospedaliero Universitaria Pisana U.O. Ematologia
city: Reggio Calabria
country: Italy
facility: AO Bianchi Melacrino Morelli UO Ematologia
city: Reggio Emilia
country: Italy
facility: AO Arcispedale S.Maria Nuova Ematologia
city: Rionero in Vulture (PZ)
country: Italy
facility: Ospedale Oncologico regionale CROB
city: Roma
country: Italy
facility: Dipartimento di biotecnologie cellulari ed ematologia Ospedale Umberto I - La Sapienza
city: Roma
country: Italy
facility: Policlinico A. Gemelli Università Cattolica del Sacro Cuore
city: Rozzano (MI)
country: Italy
facility: Clinica Humanitas
city: Torino
country: Italy
facility: A.O.San Giovanni Battista
city: Vittorio Veneto
country: Italy
facility: U.O. Oncologia Azienda ULSS7 P.O. di Vittorio Veneto
Study officials:
affiliation: Oncologia II Azienda Ospedaliera Universitaria di Modena
name: Massimo Federico, MD
role: STUDY_DIRECTOR
affiliation: Oncologia II Azienda Ospedaliera Universitaria di Modena
name: Stefano Luminari, MD
role: PRINCIPAL_INVESTIGATOR
References: